B. Brand

Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

Haemophilia B: Where are we now and what does the future hold?

Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition

Methylene blue derivatives — suitable photoantimicrobials for blood product disinfection?

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

Immunogenicity of long-lasting recombinant factor VIII products

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

Tissue Factor

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

Antimicrobial photodynamic therapy – what we know and what we don’t

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A

[Viral inactivation of fresh frozen plasma].